NEWS

Investigation on the Application Status of Rivaroxaban Generic Drug in China

Release time:

2023-02-24 11:11

 

WithI...With the increasing aging of the country, cardiovascular disease has become a serious public health problem. The application of anticoagulants is essential to prevent thrombosis and reduce the risk of stroke. Rivaroxaban (Rivaroxaban) as an oral anticoagulant, has been used inI...occupy a certain share of the national market.

 

Rivaroxaban is an oral anticoagulant and an oral anticoagulant that directly inhibits thrombin.InPreventing thrombosis and reducing the risk of stroke can prevent the production of thrombin in the blood, thereby reducing the formation of blood clots and reducing the risk of thrombosis-related diseases. Rivaroxaban is usually used to treat venous thrombosis, pulmonary embolism, atrial fibrillation, artificial heart valve replacement surgery and other conditions.

 

In China, the market for rivaroxaban is mainly dominated by Bayer's original research drugs, but with the listing of domestic rivaroxaban generics, the market competition is becoming increasingly fierce. As the original drug compound of rivaroxaban is patented in.2020Year12The monthly expiration laid the foundation for the early listing of domestic rivaroxaban generics. At present, a number of domestic pharmaceutical companies have invested in R & D and production of generic drugs of rivaroxaban, and have obtained licenses for sale in the Chinese market. Generic drugs are usually less expensive than the original drug, making the drug available to more patients.

 

According to the research of Hua Xun Zhicai consultant, Rivaroxaban'sI...The number of applications for listing in China is as high173of which the common140pieces, while the rest33The piece is under review. Among them, in the part that has been issued, the total number of successful drug certificates is55pieces. Imitations accounted for the vast majority of listing applications, reaching137pieces, imported Rivaroxaban has22new drugs only.14pieces. It can be seen that the share of imitations in the rivaroxaban market is relatively large.

 

It is worth noting that with the continuous improvement of imitation technology and product quality, the market share of imitation products is gradually increasing, and the gap between imitation products and original research drugs is gradually narrowing. At the same time, the original research is facing the dilemma of patent cliff. As the patent of rivaroxaban continues to expire, imitation enterprises also have more opportunities to enter the market.

 

On the whole, although the market prospect of rivaroxaban is facing fierce competition, its market scale and potential are still very large. With the introduction of new drugs and the increase of generic drugs, the market competition of rivaroxaban will become more and more fierce, but it is believed that more and more high-quality and safe rivaroxaban generic drugs will be available in the market, which will better serve the needs of the majority of patients.